Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Net Income (2016 - 2025)

Altimmune (ALT) has disclosed Net Income for 16 consecutive years, with -$19.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 16.77% to -$19.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$84.0 million, a 18.84% increase, with the full-year FY2024 number at -$95.1 million, down 7.53% from a year prior.
  • Net Income was -$19.0 million for Q3 2025 at Altimmune, up from -$22.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$5.4 million in Q4 2021 to a low of -$33.5 million in Q3 2021.
  • A 5-year average of -$21.5 million and a median of -$21.7 million in 2022 define the central range for Net Income.
  • Biggest YoY gain for Net Income was 29.67% in 2022; the steepest drop was 302.44% in 2022.
  • Altimmune's Net Income stood at -$5.4 million in 2021, then tumbled by 302.44% to -$21.7 million in 2022, then crashed by 46.17% to -$31.7 million in 2023, then rose by 26.41% to -$23.3 million in 2024, then increased by 18.39% to -$19.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Net Income are -$19.0 million (Q3 2025), -$22.1 million (Q2 2025), and -$19.6 million (Q1 2025).